Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent underwhelming data for CagriSema, but the Danish pharma has given itself ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

FDA-approved Wegovy® at a reduced cost in our high-quality pen." Wegovy is a highly popular medication due to its weight-loss benefits. In previous years, Novo Nordisk struggled to meet the demand for ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

Novo Nordisk Expands Discounted Wegovy Price to Brick-and-Mortar Pharmacies ... pre-filled injection pens. The new lower cash price for Wegovy covers all doses of the drug. As with the online ...

The maker of Ozempic and the weight loss drug Wegovy told the FDA on April 3 that counterfeit 1-milligram injections were ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...